Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2289091 | 0.82 | ALDH1A1 (0.50) | SLC6A2SLC6A3CES2CES1ALDH1A1 | |
| SCHEMBL10762811 | 0.82 | PTPN1 (0.48) | PTPN1SLC6A2SLC6A3HTR7CES2 | |
| SCHEMBL16553310 | 0.82 | LMNA (0.59) | PTPN1SLC6A2SLC6A3CES2ALDH1A1 | |
| SCHEMBL27200590 | 0.82 | MAPT (0.44) | PTPN1SLC6A2SLC6A3HTR7CES2 | |
| SCHEMBL442090 | 0.82 | MDM2 (0.59) | PTPN1SLC6A2SLC6A3CES2CES1 | |
| SCHEMBL342966 | 0.81 | GSK3B (0.48) | SLC6A2SLC6A3CES2CES1ALDH1A1 | |
| SCHEMBL904487 | 0.81 | HTT (0.51) | CES2CES1ALDH1A1CA1CA2 | |
| SCHEMBL27780371 | 0.81 | PTPN1 (0.47) | PTPN1SLC6A2SLC6A3CES2CES1 | |
| SCHEMBL2294689 | 0.80 | CES2 (0.51) | SLC6A2SLC6A3CES2CES1ALDH1A1 | |
| SCHEMBL904584 | 0.80 | GSK3B (0.56) | PTPN1CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103694111-B | A kind of preparation method of 4-(4-fluoro benzoyl) butyric acid | ZHEJIANG XINHECHENG CO., LTD. (CN) | 2016-02-03 | — | — | CN | claimed |
| CN-103694111-A | Method for preparing 4-(4-fluorobenzoyl) butyric acid | ZHEJIANG NHU CO LTD | 2014-04-02 | — | — | CN | claimed |
| US-8383810-B2 | Process for the synthesis of azetidinones | MERCK SHARP & DOHME CORP. (US) | 2013-02-26 | — | — | US | claimed |
| EP-1831162-B1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | MERCK SHARP & DOHME (US) | 2012-10-31 | — | — | EP | claimed |
| US-20120083601-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING-PLOUGH CORPORATION (US) | 2012-04-05 | — | — | US | claimed |
| US-20110144327-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2011-06-16 | — | — | US | claimed |
| EP-2004639-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | Teva Pharmaceutical Industries Ltd (IL) | 2008-12-24 | — | — | EP | claimed |
| US-20080032964-A1 | Process for the synthesis of azetidinone | TEVA PHARMACEUTICALS USA, INC. | 2008-02-07 | — | — | US | claimed |
| WO-2007120824-A2 | PROCESSES FOR THE SYNTHESIS OF AZETIDINONE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-10-25 | — | — | WO | claimed |
| EP-1831162-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006068990-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20060135755-A1 | Process for the synthesis of azetidinones | SCHERING CORPORATION | 2006-06-22 | — | — | US | claimed |
| EP-1137634-B1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORP (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1137634-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2001-10-04 | — | — | EP | claimed |
| US-6207822-B1 | REACTING P-FLUOROBENZOYLBUTYRIC ACID WITH PIVALOYL CHLORIDE;ACYLATION; REDUCTION; CYCLIZATION; HYDROSILATION; DEBLOCKING | SCHERING CORPORATION | 2001-03-27 | — | — | US | claimed |
| WO-2000034240-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2000-06-15 | — | — | WO | claimed |
| CN-116283948-A | Synthesis method of ezetimibe intermediate | 江苏阿尔法药业股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115960054-A | Preparation method of ezetimibe intermediate | 南通常佑药业科技有限公司 | 2023-04-14 | — | — | CN | disclosed |
| WO-2000034240-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034240-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | SCHERING CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083601-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | LSS, ASNS, CYP51A1 | PTPN1 2543/4885SLC6A2 3590/4885SLC6A3 4360/4885 |
| US-20110144327-A1 | PROCESS FOR THE SYNTHESIS OF AZETIDINONES | LSS, ASNS, CYP51A1 | PTPN1 2543/4885SLC6A2 3590/4885SLC6A3 4360/4885 |
| US-20080032964-A1 | Process for the synthesis of azetidinone | CYP46A1, APOB, CYP51A1 | PTPN1 3033/4885SLC6A2 3572/4885SLC6A3 3494/4885 |
| US-20060135755-A1 | Process for the synthesis of azetidinones | LSS, ASNS, CYP51A1 | PTPN1 2543/4885SLC6A2 3590/4885SLC6A3 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.